Inflammation and Cardiovascular Health in Women

Inclusion Criteria

• •WHIV:
• •Inclusion
• •female nascent sex
• •HIV
• •age 40-79
• •self-report of stable ART for at least 180 days prior to study entry - any regimen (no more than 30 days missed medication in the last 180 days)
• •Exclusion
• •self-reported history of MI, stroke, coronary revascularization
• •stable or unstable angina symptoms
• •a pre-existing diagnosis of diabetes, being actively treated with oral or injectable antihyperglycemic medication
• •current cocaine use
• •current use of exogenous oral, or transdermal, injected, or depot estrogen or testosterone
• •current treatment with prescription, systemic (oral, IV, or IM) steroids, or anti-inflammatory/immune suppressant medical therapies (excluding topical therapies, UV therapy, ASA-derivative therapies, or NSAIDs) for autoimmune/inflammatory diseases (psoriasis, RA, IBD, lupus), post-transplant care, asthma, or pain syndromes
• •use of oral steroids or prescription oral anti-inflammatory/immune suppressant medication for \>7 days within the past 30 days prior to entry
• •pregnant or breastfeeding
• •eGFR \< 60 ml/min/1.73 m2 calculated by 2021 CKD-EPI Creatinine
• •known severe allergy to iodinated contrast media (CCTA), dextrans/DTPA/radiometals (99mTc-tilmanocept SPECT/CT), or regadenoson/adenosine (cardiac PET/CT).
• •self-reported significant radiation exposure (\>2 CT angiograms) received within the past 12 months
• •concurrent enrollment in conflicting research study.
• •Non-HIV-infected women: